.svg)
Dabur Research Foundation: Difference between revisions
>ZI Jony m (v2.04b - Fix errors for CW project (Template contains useless word template:)) |
m (robot: Update article (please report if you notice any mistake or error in this edit)) |
||
| Line 21: | Line 21: | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
* [http://articles.economictimes.indiatimes.com/keyword/international-finance-corporation Articles about International Finance Corporation | * [http://articles.economictimes.indiatimes.com/keyword/international-finance-corporation Articles about International Finance Corporation – Economic Times<!-- Bot generated title -->] | ||
* [https://web.archive.org/web/20111102220924/http://biospectrumindia.ciol.com/content/CoverStory/111101113.asp BioSpectrumIndia | * [https://web.archive.org/web/20111102220924/http://biospectrumindia.ciol.com/content/CoverStory/111101113.asp BioSpectrumIndia – the business of biotech – Customer relationships in a competitive market<!-- Bot generated title -->] | ||
* [http://www.business-standard.com/india/news/elephant-capital-buys-stake-in-clintec-intl-for-rs-58-cr/105952/on Elephant Capital buys stake in ClinTec Intl for Rs 58 cr<!-- Bot generated title -->] | * [http://www.business-standard.com/india/news/elephant-capital-buys-stake-in-clintec-intl-for-rs-58-cr/105952/on Elephant Capital buys stake in ClinTec Intl for Rs 58 cr<!-- Bot generated title -->] | ||
* [https://web.archive.org/web/20120827052720/http://www.biospectrumasia.com/biospectrum/opinion/3204/cosmetics-testing-kills-million-animals#.UEuw9rLiZi9 Cosmetics testing kills 3.9 million animals - BioSpectrum Asia<!-- Bot generated title -->] | * [https://web.archive.org/web/20120827052720/http://www.biospectrumasia.com/biospectrum/opinion/3204/cosmetics-testing-kills-million-animals#.UEuw9rLiZi9 Cosmetics testing kills 3.9 million animals - BioSpectrum Asia<!-- Bot generated title -->] | ||
| Line 28: | Line 28: | ||
* [http://www.business-standard.com/india/news/dabur-to-re-expand-its-pharma-research/382968/ Dabur to re-expand its pharma research<!-- Bot generated title -->] | * [http://www.business-standard.com/india/news/dabur-to-re-expand-its-pharma-research/382968/ Dabur to re-expand its pharma research<!-- Bot generated title -->] | ||
== | ==Review of Literature == | ||
* {{cite journal |doi=10.1007/s12094-012-0883-2 |title=Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel |year=2012 |last1=Madaan |first1=Alka |last2=Singh |first2=Pratibha |last3=Awasthi |first3=Anshumali |last4=Verma |first4=Ritu |last5=Singh |first5=Anu T. |last6=Jaggi |first6=Manu |last7=Mishra |first7=Shiva Kant |last8=Kulkarni |first8=Sadanand |last9=Kulkarni |first9=Hrishikesh |journal=Clinical and Translational Oncology |volume=15 |issue=1 |pages=26–32 |pmid=22855169 }} | * {{cite journal |doi=10.1007/s12094-012-0883-2 |title=Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel |year=2012 |last1=Madaan |first1=Alka |last2=Singh |first2=Pratibha |last3=Awasthi |first3=Anshumali |last4=Verma |first4=Ritu |last5=Singh |first5=Anu T. |last6=Jaggi |first6=Manu |last7=Mishra |first7=Shiva Kant |last8=Kulkarni |first8=Sadanand |last9=Kulkarni |first9=Hrishikesh |journal=Clinical and Translational Oncology |volume=15 |issue=1 |pages=26–32 |pmid=22855169 }} | ||
* {{cite journal |doi=10.1080/14756360802696802 |title=Anticancer and immunomodulatory activities of novel 1,8-naphthyridine derivatives |year=2009 |last1=Kumar |first1=Vivek |last2=Madaan |first2=Alka |last3=Sanna |first3=Vinod K. |last4=Vishnoi |first4=Manupriya |last5=Joshi |first5=Narendra |last6=Singh |first6=Anu T. |last7=Jaggi |first7=Manu |last8=Sharma |first8=Pramod K. |last9=Irchhaiya |first9=Raghuveer |last10=Burman |first10=Anand C. |journal=Journal of Enzyme Inhibition and Medicinal Chemistry |volume=24 |issue=5 |pages=1169–78 |pmid=19555167|display-authors=8 }} | * {{cite journal |doi=10.1080/14756360802696802 |title=Anticancer and immunomodulatory activities of novel 1,8-naphthyridine derivatives |year=2009 |last1=Kumar |first1=Vivek |last2=Madaan |first2=Alka |last3=Sanna |first3=Vinod K. |last4=Vishnoi |first4=Manupriya |last5=Joshi |first5=Narendra |last6=Singh |first6=Anu T. |last7=Jaggi |first7=Manu |last8=Sharma |first8=Pramod K. |last9=Irchhaiya |first9=Raghuveer |last10=Burman |first10=Anand C. |journal=Journal of Enzyme Inhibition and Medicinal Chemistry |volume=24 |issue=5 |pages=1169–78 |pmid=19555167|display-authors=8 }} | ||
Latest revision as of 02:23, 25 May 2022
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
| File:Dabur Research Foundation logo.png | |
| Founded | 1979 |
|---|---|
| Headquarters | Sahibabad, Ghaziabad - 201010 (UP) , |
| Parent | Dabur India Limited |
| Website | daburresearch.in |
Dabur Research Foundation (DRF) is an Indian contract research organization offering pre-clinical services in drug discovery and development. It was established in 1979 to spearhead the research and development activities of Dabur, India's largest Ayurvedic medicine manufacturer.
References[edit]
- Articles about International Finance Corporation – Economic Times
- BioSpectrumIndia – the business of biotech – Customer relationships in a competitive market
- Elephant Capital buys stake in ClinTec Intl for Rs 58 cr
- Cosmetics testing kills 3.9 million animals - BioSpectrum Asia
- Burmans plan Rs 925-crore healthcare fund
- Dabur to re-expand its pharma research
Review of Literature[edit]
- Madaan, Alka; Singh, Pratibha; Awasthi, Anshumali; Verma, Ritu; Singh, Anu T.; Jaggi, Manu; Mishra, Shiva Kant; Kulkarni, Sadanand; Kulkarni, Hrishikesh (2012). "Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel". Clinical and Translational Oncology. 15 (1): 26–32. doi:10.1007/s12094-012-0883-2. PMID 22855169.
- Kumar, Vivek; Madaan, Alka; Sanna, Vinod K.; Vishnoi, Manupriya; Joshi, Narendra; Singh, Anu T.; Jaggi, Manu; Sharma, Pramod K.; et al. (2009). "Anticancer and immunomodulatory activities of novel 1,8-naphthyridine derivatives". Journal of Enzyme Inhibition and Medicinal Chemistry. 24 (5): 1169–78. doi:10.1080/14756360802696802. PMID 19555167.
- Bansal, Tripta; Jaggi, Manu; Khar, Roop K; Talegaonkar, Sushama (2009). "Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy". Journal of Pharmacy & Pharmaceutical Sciences. 12 (1): 46–78. CiteSeerX 10.1.1.557.474. PMID 19470292.
External links[edit]
 | This article about an organisation in India is a stub. You can help Wikipedia by expanding it. |